AI Health Products Are Multiplying. Nobody's Defending Them.

Perplexity launched a Health AI feature this week that pulls from your Apple Health data to offer personalized medical suggestions. Fitbit gave its AI coach access to medical records. Both announcements hit the feed within days of each other, and both were met with the same response: a dry, rhetorical "what could go wrong" from people who'd already decided the answer. What's worth noting isn't the skepticism — it's the silence where the counterargument should be. Nobody showed up to defend these products on their merits. The critics aren't winning a debate; they're filling a room that no one else entered.

That absence shapes everything about this beat right now. Reframing the Fitbit launch as "sharing your medical records with a virtual personal trainer" is the kind of joke that does real analytical work — but jokes fill a vacuum. When product defenders are nowhere and regulators are quiet, skeptics end up performing consensus for each other, which looks like a dominant mood but functions more like an echo. The actual argument — whether AI-assisted health tools can be built responsibly for consumer use, and on what terms — isn't happening anywhere visible.

Running underneath the product conversation is something harder to laugh off. Someone who'd been talking to healthcare vendors noted this week that many senior citizens will encounter agentic AI for the first time when they call a healthcare provider — not through a phone they chose to use or an app they downloaded, but through a system selected by an institution. That observation, quiet as it was, named the real asymmetry: the people least equipped to evaluate AI-generated medical guidance are positioned to receive it first and at scale. The same week brought a study showing telemedicine still failing rural and disadvantaged communities — not connected to the vendor observation by anyone in the feed, but sitting next to it in a way that's hard to ignore.

Meanwhile, an AMA survey finding that eighty-one percent of physicians now use AI circulated with minimal friction, wrapped in a gentle warning about patients who self-diagnose. The framing — doctors as competent stewards, patients as potential hazards — is a specific institutional argument dressed as a caution, and it passed largely unexamined. The clinical research posts circulate in an entirely separate current: agentic rare disease diagnosis, AI glaucoma screening approaching specialist accuracy, VR-integrated treatment plans. These are genuinely significant findings, but they generate almost no crossover with the consumer skeptics or the access advocates. The researchers aren't reading the Fitbit threads; the Fitbit skeptics aren't reading the preprints.

What this beat is producing, for now, is a slow accumulation of consumer products that each generate a small, self-contained wave of eye-rolls and then recede. The Perplexity and Fitbit launches are the most visible shared focal point in weeks, and even they haven't cracked into genuine controversy. That will change the first time one of these products generates a documented, high-profile harm — a missed diagnosis, a dangerous suggestion, a vulnerable patient acted on something they shouldn't have. At that point, the question of who was supposed to be defending these products, regulating them, and warning people about them will become very loud very fast. Right now, everyone's positioned to say they were skeptical all along.